FI3355913T3 - Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä - Google Patents
Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä Download PDFInfo
- Publication number
- FI3355913T3 FI3355913T3 FIEP16784320.0T FI16784320T FI3355913T3 FI 3355913 T3 FI3355913 T3 FI 3355913T3 FI 16784320 T FI16784320 T FI 16784320T FI 3355913 T3 FI3355913 T3 FI 3355913T3
- Authority
- FI
- Finland
- Prior art keywords
- igm
- chain
- adme
- binding molecule
- igg
- Prior art date
Links
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 claims 14
- 102100029571 Immunoglobulin J chain Human genes 0.000 claims 14
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 102000004338 Transferrin Human genes 0.000 claims 3
- 108090000901 Transferrin Proteins 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- QMXCRMQIVATQMR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-pyridin-2-ylsulfanylpropanoate Chemical group O=C1CCC(=O)N1OC(=O)CCSC1=CC=CC=N1 QMXCRMQIVATQMR-UHFFFAOYSA-N 0.000 claims 2
- 102100021257 Beta-secretase 1 Human genes 0.000 claims 2
- 101710150192 Beta-secretase 1 Proteins 0.000 claims 2
- 102000018866 Hyaluronan Receptors Human genes 0.000 claims 2
- 108010013214 Hyaluronan Receptors Proteins 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 2
- 102000016267 Leptin Human genes 0.000 claims 2
- 108010092277 Leptin Proteins 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 claims 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims 1
- NCQDNRMSPJIZKR-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]sulfanyl]pentanoic acid Chemical compound OC(=O)CCC(C)SC1C=CC=CN1N1C(=O)CCC1=O NCQDNRMSPJIZKR-UHFFFAOYSA-N 0.000 claims 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 102000003746 Insulin Receptor Human genes 0.000 claims 1
- 108010001127 Insulin Receptor Proteins 0.000 claims 1
- 102100031775 Leptin receptor Human genes 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 102100032807 Tumor necrosis factor-inducible gene 6 protein Human genes 0.000 claims 1
- 101710169430 Tumor necrosis factor-inducible gene 6 protein Proteins 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 150000001299 aldehydes Chemical class 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 238000001212 derivatisation Methods 0.000 claims 1
- 125000005442 diisocyanate group Chemical group 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 150000002222 fluorine compounds Chemical class 0.000 claims 1
- 229920002674 hyaluronan Polymers 0.000 claims 1
- 229960003160 hyaluronic acid Drugs 0.000 claims 1
- 150000002463 imidates Chemical class 0.000 claims 1
- 108010019813 leptin receptors Proteins 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- CNHYKKNIIGEXAY-UHFFFAOYSA-N thiolan-2-imine Chemical compound N=C1CCCS1 CNHYKKNIIGEXAY-UHFFFAOYSA-N 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562235518P | 2015-09-30 | 2015-09-30 | |
| PCT/US2016/055041 WO2017059380A1 (en) | 2015-09-30 | 2016-09-30 | Binding molecules with modified j-chain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3355913T3 true FI3355913T3 (fi) | 2024-12-02 |
Family
ID=57153542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP16784320.0T FI3355913T3 (fi) | 2015-09-30 | 2016-09-30 | Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10618978B2 (show.php) |
| EP (2) | EP3824903A1 (show.php) |
| JP (2) | JP7065766B2 (show.php) |
| CN (1) | CN108463245A (show.php) |
| AU (2) | AU2016329197B2 (show.php) |
| CA (1) | CA2999284C (show.php) |
| DK (1) | DK3355913T3 (show.php) |
| ES (1) | ES2996834T3 (show.php) |
| FI (1) | FI3355913T3 (show.php) |
| HK (1) | HK1252791A1 (show.php) |
| HU (1) | HUE069387T2 (show.php) |
| PL (1) | PL3355913T3 (show.php) |
| PT (1) | PT3355913T (show.php) |
| SI (1) | SI3355913T1 (show.php) |
| WO (1) | WO2017059380A1 (show.php) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
| CN105992772A (zh) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA多特异性结合分子 |
| RU2761118C2 (ru) | 2014-04-03 | 2021-12-06 | АйДжиЭм БАЙОСАЙЕНСИЗ, ИНК. | Модифицированная j-цепь |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| SG10202109717TA (en) * | 2015-03-04 | 2021-10-28 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| KR102558839B1 (ko) | 2015-03-25 | 2023-07-25 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도 |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| DK3355913T3 (da) * | 2015-09-30 | 2024-12-02 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| IL262295B2 (en) | 2016-05-09 | 2023-09-01 | Igm Biosciences Inc | Antibodies against pd–l1 |
| CN110536900B (zh) | 2017-04-07 | 2024-06-11 | Igm生物科学股份有限公司 | 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区 |
| JP7376490B2 (ja) * | 2018-03-01 | 2023-11-08 | アイジーエム バイオサイエンシズ インコーポレイテッド | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
| MX2022001934A (es) | 2019-08-15 | 2022-03-11 | Igm Biosciences Inc | Moleculas de union multimericas inmunoestimuladoras. |
| JP7585305B2 (ja) * | 2019-08-17 | 2024-11-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用 |
| JP2022545682A (ja) * | 2019-08-23 | 2022-10-28 | アイジーエム バイオサイエンシズ インコーポレイテッド | ＩｇＭグリコバリアント |
| EP4087608A4 (en) * | 2020-01-06 | 2024-02-14 | IGM Biosciences, Inc. | HIGHLY SIALYLATED MULTIMER BINDING MOLECULES |
| BR112022021392A2 (pt) | 2020-04-22 | 2022-12-06 | Igm Biosciences Inc | Moléculas de ligação multiméricas de agonista de pd-1 |
| JP7651145B2 (ja) * | 2021-04-20 | 2025-03-26 | コリア ユニバーシティ リサーチ アンド ビジネス ファウンデーション | 向上した癌細胞死滅効能を有する非対称抗体 |
| WO2022256740A1 (en) | 2021-06-04 | 2022-12-08 | Curia Ip Holdings, Llc | Polymeric fusion proteins and compositions for inducing an immune response against infection |
| JP2024528217A (ja) * | 2021-08-03 | 2024-07-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗体および使用方法 |
Family Cites Families (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8719963D0 (en) | 1987-08-24 | 1987-09-30 | Cattaneo A | Recombinant dna products |
| US5831034A (en) | 1987-11-13 | 1998-11-03 | Hermann Katinger | Human monoclonal anti-HIV-I-antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DK0642585T3 (da) | 1992-05-18 | 2006-05-15 | Genentech Inc | Aktiviering af oligomeriserende receptorer ved anvendelse af fusionerede receptorligander |
| US6476198B1 (en) | 1993-07-13 | 2002-11-05 | The Scripps Research Institute | Multispecific and multivalent antigen-binding polypeptide molecules |
| UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| AU697387C (en) | 1994-09-16 | 2006-03-02 | Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 | Polypeptides with Fc binding ability |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| IL111196A0 (en) | 1994-10-07 | 1994-12-29 | Yeda Res & Dev | Peptides and pharmaceutical compositions comprising them |
| US6808709B1 (en) | 1994-12-30 | 2004-10-26 | The Regents Of The University Of California | Immunoglobulins containing protection proteins and their use |
| US6165463A (en) | 1997-10-16 | 2000-12-26 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| WO1996033219A1 (en) | 1995-04-19 | 1996-10-24 | Polymun Scientific Immunbiologische Forschung Gmbh | Monoclonal antibodies against hiv-1 and vaccines made thereof |
| US20050003431A1 (en) | 1996-08-16 | 2005-01-06 | Wucherpfennig Kai W. | Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor |
| US8212004B2 (en) | 1999-03-02 | 2012-07-03 | Human Genome Sciences, Inc. | Neutrokine-alpha fusion proteins |
| EP1015493A1 (en) | 1997-01-10 | 2000-07-05 | EPIcyte Pharmaceutical, Inc. | Novel epithelial tissue targeting agent |
| US6045774A (en) * | 1997-01-10 | 2000-04-04 | Epicyte Pharmaceutical Inc. | J chain polypeptide targeting molecule linked to an imaging agent |
| US20040009166A1 (en) | 1997-04-30 | 2004-01-15 | Filpula David R. | Single chain antigen-binding polypeptides for polymer conjugation |
| WO1999054484A1 (en) | 1998-04-20 | 1999-10-28 | The Regents Of The University Of California | Modified immunoglobulin molecules and methods for use thereof |
| EP1354598A3 (en) | 1999-01-07 | 2003-11-19 | ZymoGenetics, Inc. | Therapeutic uses of BR43X2 soluble receptors |
| WO2000061637A1 (en) | 1999-04-14 | 2000-10-19 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
| DE05075555T1 (de) | 1999-06-09 | 2007-02-08 | Immunomedics, Inc. | Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern |
| WO2001012820A1 (en) | 1999-08-17 | 2001-02-22 | Health Research Institute | Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity |
| CA2589418A1 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| PL357939A1 (en) | 2000-04-11 | 2004-08-09 | Genentech, Inc. | Multivalent antibodies and uses therefor |
| US20020168367A1 (en) | 2000-04-28 | 2002-11-14 | Planet Biotechnology Incorporated | Novel immunoadhesins for treating and preventing viral and bacterial diseases |
| CA2407426A1 (en) | 2000-04-28 | 2001-11-08 | Planet Biotechnology, Inc. | Immunoadhesin for the prevention of rhinovirus infection |
| US7947463B2 (en) | 2000-05-10 | 2011-05-24 | Signe Biopharma, Inc. | Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers |
| JP2004502450A (ja) | 2000-07-10 | 2004-01-29 | ノバルティス アクチエンゲゼルシャフト | ターゲッティング遺伝子送達のための二官能性分子およびそれと複合化されたベクター |
| WO2005056601A2 (en) | 2003-12-05 | 2005-06-23 | Schreiber John R | Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse? |
| WO2002020619A2 (en) | 2000-09-07 | 2002-03-14 | Schreiber John R | HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| DK1366067T3 (da) | 2001-03-07 | 2012-10-22 | Merck Patent Gmbh | Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed |
| US7402312B2 (en) * | 2001-04-13 | 2008-07-22 | Human Genome Sciences, Inc. | Antibodies to vascular endothelial growth factor 2 (VEGF-2) |
| US20050129616A1 (en) | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
| NZ513418A (en) | 2001-08-07 | 2004-04-30 | Univ Massey | Vaccine comprising proteins from mycobacterium paratuberculosis |
| EP2360169B1 (en) | 2001-10-23 | 2015-10-14 | Psma Development Company, L.L.C. | PSMA antibodies |
| WO2003068821A2 (en) | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| EP2865688A1 (en) | 2002-03-01 | 2015-04-29 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| ATE417067T1 (de) | 2002-03-01 | 2008-12-15 | Immunomedics Inc | Rs7 antikörper |
| SI1503794T1 (sl) | 2002-04-12 | 2012-09-28 | Medarex Inc | Postopek zdravljenja z uporabo ctla-4 antiteles |
| EP2301968A3 (en) | 2002-06-14 | 2011-06-29 | Immunomedics, Inc. | Humanized monoclonal antibody HPAM4 |
| US7601351B1 (en) * | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
| ES2442615T5 (es) | 2002-07-18 | 2023-03-16 | Merus Nv | Producción recombinante de mezclas de anticuerpos |
| JP5138867B2 (ja) | 2002-08-01 | 2013-02-06 | イミューノメディクス、インコーポレイテッド | α−フェトタンパク質Ｉｍｍｕ３１抗体および融合タンパク質ならびにその使用方法 |
| AU2003275029A1 (en) | 2002-09-27 | 2004-04-19 | Brigham And Women's Hospital, Inc. | Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues |
| US7541440B2 (en) | 2002-09-30 | 2009-06-02 | Immunomedics, Inc. | Chimeric, human and humanized anti-granulocyte antibodies and methods of use |
| US20050014932A1 (en) | 2003-05-15 | 2005-01-20 | Iogenetics, Llc | Targeted biocides |
| AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
| WO2004104046A1 (en) | 2003-05-23 | 2004-12-02 | Crucell Holland B.V. | Production of recombinant igm in per.c6 cells |
| EP2204190A1 (en) | 2003-07-15 | 2010-07-07 | Chugai Seiyaku Kabushiki Kaisha | IgM production by transformed cells and methods for quantifying said IgM production |
| EP2216342B1 (en) | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
| JP4671864B2 (ja) | 2003-10-09 | 2011-04-20 | 中外製薬株式会社 | タンパク質溶液の安定化方法 |
| PL1673398T3 (pl) | 2003-10-16 | 2011-05-31 | Amgen Res Munich Gmbh | Multispecyficzne deimmunizowane cząsteczki wiążące CD3 |
| FR2861255B1 (fr) | 2003-10-24 | 2006-02-17 | Centre Nat Rech Scient | Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications. |
| US20050249723A1 (en) | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2551502T3 (es) | 2004-11-05 | 2015-11-19 | Igm Biosciences, Inc. | Formación de heridas en la membrana celular inducida por anticuerpos |
| US7251164B2 (en) | 2004-11-10 | 2007-07-31 | Innovative Silicon S.A. | Circuitry for and method of improving statistical distribution of integrated circuits |
| US20090311280A1 (en) | 2004-12-09 | 2009-12-17 | La Jolla Institute For Allergy And Immunology | Novel tnf receptor regulatory domain |
| JP5214252B2 (ja) | 2005-03-03 | 2013-06-19 | イミューノメディクス、インコーポレイテッド | ヒト化ｌ２４３抗体 |
| US8349332B2 (en) | 2005-04-06 | 2013-01-08 | Ibc Pharmaceuticals, Inc. | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases |
| US8333971B2 (en) | 2006-05-15 | 2012-12-18 | Immunomedics, Inc. | Methods and compositions for treatment of human immunodeficiency virus infection with conjugated antibodies or antibody fragments |
| JP2008541758A (ja) * | 2005-06-02 | 2008-11-27 | アストラゼネカ エービー | Ｃｄ２０に対する抗体およびその使用 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| TW200732350A (en) | 2005-10-21 | 2007-09-01 | Amgen Inc | Methods for generating monovalent IgG |
| EP1981532A4 (en) | 2005-12-21 | 2010-06-30 | Medimmune Llc | EPHA2 MOLECULES AND USES THEREOF |
| AU2007252295B2 (en) | 2006-05-19 | 2013-07-25 | Central Adelaide Local Health Network Incorporated | Selective modulation of receptor signalling |
| MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| WO2008019147A2 (en) * | 2006-08-04 | 2008-02-14 | Amylin Pharmaceuticals, Inc. | Use of exendins, exendin agonists and glp-1 receptor agonists for altering the concentration of fibrinogen |
| ES2902063T3 (es) | 2006-09-08 | 2022-03-24 | Abbvie Bahamas Ltd | Proteínas de unión a interleucina-13 |
| US9382327B2 (en) | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
| BRPI0716680A2 (pt) | 2006-11-02 | 2013-09-24 | Daniel J Capon | "composto, multÍmero, composiÇço, mÉtodo de afetar a atividade de um alvo, complexo, processo de produÇço do composto, mÉtodo de produÇço de um extensço de aminoÁcidos consecutivos, processo de produÇço de uma extensço de aminoacidos consecutivos , processo para a produÇço de um composto , mÉtodo de produÇço de uma proteina e polipeptÍdeo" |
| US20080145420A1 (en) * | 2006-12-13 | 2008-06-19 | Simon Michael R | HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES |
| WO2008114011A2 (en) * | 2007-03-19 | 2008-09-25 | Medimmune Limited | Fc polypeptide variants obtained by ribosome display methodology |
| WO2008135963A2 (en) | 2007-05-02 | 2008-11-13 | Hemogem Inc. | Fibrinogen for treatment of bleeding in trauma and platelet disorders |
| WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
| CA2698419C (en) | 2007-09-07 | 2019-11-12 | Edward Dolk | Binding molecules with multiple binding sites, compositions comprising the same and uses thereof |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| WO2009062151A1 (en) | 2007-11-08 | 2009-05-14 | Cytimmune Sciences, Inc. | Compositions and methods for generating antibodies |
| EP2254592B1 (en) | 2008-02-28 | 2019-06-05 | Dako Denmark A/S | Mhc multimers in borrelia diagnostics and disease |
| ITTO20080313A1 (it) | 2008-04-22 | 2009-10-23 | Marco Colombatti | Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi |
| MX2011000230A (es) | 2008-07-11 | 2011-03-02 | Sea Lane Biotechnologies Llc | Construcciones y bibliotecas que comprenden secuencias de cadena ligera kappa surrogadas de anticuerpo. |
| US10369204B2 (en) | 2008-10-02 | 2019-08-06 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| EP2411024A4 (en) * | 2009-03-24 | 2013-02-27 | Bayer Healthcare Llc | Variants of factor viii and associated methods of use |
| WO2011071957A1 (en) | 2009-12-07 | 2011-06-16 | Sea Lane Biotechnologies, Llc | Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties |
| JP5856073B2 (ja) | 2009-12-29 | 2016-02-09 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | Ｒｏｎ結合構築体およびその使用方法 |
| MX341687B (es) | 2010-02-10 | 2016-08-30 | Immunogen Inc | "anticuerpos cd20 y su utilización". |
| AU2011215750A1 (en) | 2010-02-11 | 2012-08-23 | Alexion Pharmaceuticals, Inc. | Therapeutic methods using an ti-CD200 antibodies |
| ES2662100T3 (es) | 2010-10-19 | 2018-04-05 | Mayo Foundation For Medical Education And Research | Anticuerpos humanos y diagnósticos y usos terapéuticos de los mismos para el tratamiento de la enfermedad neurológica |
| UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
| CA2853114A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Bispecific immunobinders directed against tnf and il-17 |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| EP2791172B1 (en) | 2011-12-16 | 2017-07-19 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| TWI606064B (zh) | 2012-02-08 | 2017-11-21 | Ｉｇｍ生物科技公司 | 細胞死亡誘導分子（ｃｄｉｍ）結合蛋白類及彼等之用途 |
| WO2013150138A1 (en) | 2012-04-05 | 2013-10-10 | Gottfried Himmler | Secretory immunoglobulin complex |
| EP3305323B1 (en) | 2012-04-17 | 2021-02-17 | Mayo Foundation for Medical Education and Research | Human antibodies and specific binding sequences thereof for use in stroke and ischemia or ischemic conditions |
| JP5855239B2 (ja) * | 2012-04-23 | 2016-02-09 | 株式会社Ｎｒｌファーマ | ラクトフェリン融合タンパク質及びその製造方法 |
| WO2013188870A2 (en) | 2012-06-15 | 2013-12-19 | Beth Israel Deaconess Medical Center, Inc. | IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME |
| JP2015524821A (ja) | 2012-08-02 | 2015-08-27 | ジェイエヌ バイオサイエンシーズ エルエルシー | システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| WO2014124457A1 (en) | 2013-02-11 | 2014-08-14 | University Of Louisville Research Foundation, Inc. | Methods for producing antibodies |
| US9487773B2 (en) | 2013-03-01 | 2016-11-08 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Cell-based methods for coupling protein interactions and binding molecule selection |
| WO2014165093A2 (en) * | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
| GB201311487D0 (en) | 2013-06-27 | 2013-08-14 | Alligator Bioscience Ab | Bispecific molecules |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| MX2016008667A (es) | 2013-12-30 | 2017-02-02 | Epimab Biotherapeutics Inc | Inmunoglobulina con fab en tandem y usos de esta. |
| US10167333B2 (en) | 2014-01-16 | 2019-01-01 | Mario Umberto Francesco Mondelli | Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen |
| CN105992772A (zh) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA多特异性结合分子 |
| PH12016501545B1 (en) | 2014-03-14 | 2023-12-06 | Immutep Sas | Antibody molecules to lag-3 and uses thereof |
| RU2761118C2 (ru) | 2014-04-03 | 2021-12-06 | АйДжиЭм БАЙОСАЙЕНСИЗ, ИНК. | Модифицированная j-цепь |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor-α receptor binding molecules and their uses |
| SG10202109717TA (en) * | 2015-03-04 | 2021-10-28 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| KR102558839B1 (ko) | 2015-03-25 | 2023-07-25 | 아이쥐엠 바이오사이언스 인코포레이티드 | 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도 |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| CA2991973C (en) | 2015-07-12 | 2021-12-07 | Suzhou M-Conj Biotech Co., Ltd. | Bridge linkers for conjugation of a cell-binding molecule |
| ES2819870T3 (es) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Moléculas de unión con cadena J modificada |
| DK3355913T3 (da) | 2015-09-30 | 2024-12-02 | Igm Biosciences Inc | Bindingsmolekyler med modificeret j-kæde |
| IL262295B2 (en) | 2016-05-09 | 2023-09-01 | Igm Biosciences Inc | Antibodies against pd–l1 |
| US20190338041A1 (en) | 2016-07-20 | 2019-11-07 | Igm Biosciences, Inc. | Multimeric cd40 binding molecules and uses thereof |
| MX2019000796A (es) | 2016-07-20 | 2019-06-03 | Igm Biosciences Inc | Moleculas multimericas de union a ox40 y usos de las mismas. |
| US20190330360A1 (en) | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric gitr binding molecules and uses thereof |
| EP3487298A4 (en) | 2016-07-20 | 2020-03-11 | IGM Biosciences, Inc. | MULTIMERE CD137 / 4-1BB-BINDING MOLECULES AND USES THEREOF |
| CN110536900B (zh) | 2017-04-07 | 2024-06-11 | Igm生物科学股份有限公司 | 调节补体依赖性细胞溶解效应子功能的修饰的人igm恒定区 |
| KR20200123782A (ko) | 2018-02-26 | 2020-10-30 | 아이쥐엠 바이오사이언스 인코포레이티드 | 암치료를 위해 화학치료제와 병용된 다중결합 항-dr5 결합분자의 용도 |
| JP7376490B2 (ja) | 2018-03-01 | 2023-11-08 | アイジーエム バイオサイエンシズ インコーポレイテッド | ＩｇＭ血清半減期に影響を及ぼすＩｇＭ Ｆｃ及びＪ鎖の変異 |
| EP3870223A4 (en) | 2018-10-23 | 2022-08-24 | IGM Biosciences, Inc. | MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES |
| US20220106398A1 (en) | 2019-02-08 | 2022-04-07 | Igm Biosciences, Inc. | Anti-gitr antigen-binding domains and uses thereof |
| MX2022001934A (es) | 2019-08-15 | 2022-03-11 | Igm Biosciences Inc | Moleculas de union multimericas inmunoestimuladoras. |
| JP7585305B2 (ja) | 2019-08-17 | 2024-11-18 | アイジーエム バイオサイエンシズ インコーポレイテッド | 多量体の二重特異性抗ｃｄ１２３結合分子及びその使用 |
| JP2022545682A (ja) | 2019-08-23 | 2022-10-28 | アイジーエム バイオサイエンシズ インコーポレイテッド | ＩｇＭグリコバリアント |
| CA3151237A1 (en) | 2019-09-19 | 2021-03-25 | Ramesh Baliga | Multimeric antibodies with enhanced selectivity for cells with high target density |
| EP4087608A4 (en) | 2020-01-06 | 2024-02-14 | IGM Biosciences, Inc. | HIGHLY SIALYLATED MULTIMER BINDING MOLECULES |
| BR112022021392A2 (pt) | 2020-04-22 | 2022-12-06 | Igm Biosciences Inc | Moléculas de ligação multiméricas de agonista de pd-1 |
| US20230174660A1 (en) | 2020-05-12 | 2023-06-08 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer |
| WO2022026475A2 (en) | 2020-07-27 | 2022-02-03 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
| WO2022109023A1 (en) | 2020-11-17 | 2022-05-27 | Igm Biosciences, Inc. | Uses of effector cell engaging molecules with moieties of differing potencies |
| AU2022221633A1 (en) | 2021-02-17 | 2023-08-10 | Igm Biosciences, Inc. | Anti-cd123 binding molecules and uses thereof |
| US20220267415A1 (en) | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| WO2023064766A1 (en) | 2021-10-11 | 2023-04-20 | Igm Biosciences, Inc. | Lateral flow device and uses thereof |
| WO2023064900A1 (en) | 2021-10-15 | 2023-04-20 | Igm Biosciences, Inc. | Methods of use of multimeric anti-pd-l1 binding molecules |
| GEAP202416592A (en) | 2022-02-03 | 2024-11-11 | Igm Biosciences Inc | Anti-cd38 binding molecules and uses thereof |
| WO2023178253A2 (en) | 2022-03-18 | 2023-09-21 | Igm Biosciences, Inc. | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy |
| WO2024073700A2 (en) | 2022-09-30 | 2024-04-04 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd20/anti-cd3 antibodies |
| WO2024138072A1 (en) | 2022-12-22 | 2024-06-27 | Igm Biosciences, Inc. | Methods of treating autoimmune disorders using multimeric anti-cd38/anti-cd3 antibodies |
| WO2024148339A1 (en) | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | Use of a multimeric anti-dr5 antibody for treating cancer |
| WO2024148336A1 (en) | 2023-01-06 | 2024-07-11 | Igm Biosciences, Inc. | T cell costimulatory multimeric binding molecules and uses thereof |
| WO2024229151A2 (en) | 2023-05-02 | 2024-11-07 | Igm Biosciences, Inc. | Multimeric coronavirus binding molecules and uses thereof |
-
2016
- 2016-09-30 DK DK16784320.0T patent/DK3355913T3/da active
- 2016-09-30 JP JP2018516668A patent/JP7065766B2/ja active Active
- 2016-09-30 HU HUE16784320A patent/HUE069387T2/hu unknown
- 2016-09-30 CN CN201680069842.XA patent/CN108463245A/zh active Pending
- 2016-09-30 HK HK18111023.8A patent/HK1252791A1/zh unknown
- 2016-09-30 US US15/764,859 patent/US10618978B2/en active Active
- 2016-09-30 SI SI201631864T patent/SI3355913T1/sl unknown
- 2016-09-30 PL PL16784320.0T patent/PL3355913T3/pl unknown
- 2016-09-30 FI FIEP16784320.0T patent/FI3355913T3/fi active
- 2016-09-30 PT PT167843200T patent/PT3355913T/pt unknown
- 2016-09-30 EP EP20204954.0A patent/EP3824903A1/en not_active Withdrawn
- 2016-09-30 ES ES16784320T patent/ES2996834T3/es active Active
- 2016-09-30 AU AU2016329197A patent/AU2016329197B2/en active Active
- 2016-09-30 EP EP16784320.0A patent/EP3355913B1/en active Active
- 2016-09-30 WO PCT/US2016/055041 patent/WO2017059380A1/en not_active Ceased
- 2016-09-30 CA CA2999284A patent/CA2999284C/en active Active
-
2020
- 2020-01-16 US US16/745,059 patent/US11542342B2/en active Active
-
2021
- 2021-01-20 AU AU2021200348A patent/AU2021200348B2/en active Active
-
2022
- 2022-04-26 JP JP2022072055A patent/JP7314356B2/ja active Active
- 2022-11-11 US US18/054,776 patent/US12486336B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200255546A1 (en) | 2020-08-13 |
| HUE069387T2 (hu) | 2025-03-28 |
| ES2996834T3 (en) | 2025-02-13 |
| US10618978B2 (en) | 2020-04-14 |
| AU2016329197A1 (en) | 2018-04-12 |
| US12486336B2 (en) | 2025-12-02 |
| PL3355913T3 (pl) | 2025-02-17 |
| JP7314356B2 (ja) | 2023-07-25 |
| US20230203201A1 (en) | 2023-06-29 |
| CA2999284A1 (en) | 2017-04-06 |
| EP3355913B1 (en) | 2024-10-30 |
| JP2018535932A (ja) | 2018-12-06 |
| CN108463245A (zh) | 2018-08-28 |
| SI3355913T1 (sl) | 2025-01-31 |
| PT3355913T (pt) | 2024-12-18 |
| AU2021200348A1 (en) | 2021-03-18 |
| DK3355913T3 (da) | 2024-12-02 |
| EP3824903A1 (en) | 2021-05-26 |
| JP7065766B2 (ja) | 2022-05-12 |
| WO2017059380A1 (en) | 2017-04-06 |
| CA2999284C (en) | 2023-06-13 |
| AU2016329197B2 (en) | 2021-01-21 |
| EP3355913A1 (en) | 2018-08-08 |
| JP2022105085A (ja) | 2022-07-12 |
| HK1252791A1 (zh) | 2019-06-06 |
| AU2021200348B2 (en) | 2024-07-11 |
| US20180265596A1 (en) | 2018-09-20 |
| US11542342B2 (en) | 2023-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3355913T3 (fi) | Muokatun j-ketjun sisältäviä sitoutuvia molekyylejä | |
| US11986535B2 (en) | Method of producing an immunoligand/payload conjugate | |
| JP2018535932A5 (show.php) | ||
| Wagner et al. | Bispecific antibody generated with sortase and click chemistry has broad antiinfluenza virus activity | |
| AU2021201710B9 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
| Monnier et al. | In vivo applications of single chain Fv (variable domain)(scFv) fragments | |
| Forte et al. | Tuning the hydrolytic stability of next generation maleimide cross-linkers enables access to albumin-antibody fragment conjugates and tri-scFvs | |
| EP2994164B1 (en) | Bispecific her2 and her3 antigen binding constructs | |
| Mertens | Tribodies: fab–scfv fusion proteins as a platform to create multifunctional pharmaceuticals | |
| US8728479B2 (en) | Antigen-binding proteins comprising recombinant protein scaffolds | |
| Kornberger et al. | Sortase-catalyzed in vitro functionalization of a HER2-specific recombinant Fab for tumor targeting of the plant cytotoxin gelonin | |
| Woitok et al. | The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F | |
| JP2019013232A (ja) | 志賀毒素ａサブユニットエフェクター領域を含む多価ｃｄ２０結合分子及びそれらの強化組成物 | |
| RU2020103344A (ru) | Конъюгаты антител с лекарственными средствами, характеризующиеся высокой in vivo переносимостью | |
| SI2802606T1 (en) | Improves the transfer of healing molecules through the hematoencephalic barrier | |
| RU2010127156A (ru) | Антитела против вируса гриппа и их применение | |
| BRPI0214137B8 (pt) | anticorpo monoclonal humano ou porção de ligação a antígeno do mesmo que se liga especificamente ao cd40 humano e o ativa, linhagem celular de hibridoma isolado, composição farmacêutica compreendendo os mesmos, uso dos mesmos na fabricação de um medicamento e método de fabricação dos referidos anticorpos ou porção de ligação a antígeno do mesmo | |
| US20100015661A1 (en) | Antibody-rnase-conjugate | |
| JP2014502607A (ja) | 抗ｄｉｇ抗体およびペプチドと結合体化しているジゴキシゲニンの複合体の薬学的組成物 | |
| Humphreys et al. | Alternative antibody Fab′ fragment PEGylation strategies: combination of strong reducing agents, disruption of the interchain disulphide bond and disulphide engineering | |
| Fuchs et al. | A cleavable molecular adapter reduces side effects and concomitantly enhances efficacy in tumor treatment by targeted toxins in mice | |
| Panjideh et al. | Improved therapy of B-cell non-hodgkin lymphoma by obinutuzumab-dianthin conjugates in combination with the endosomal escape enhancer SO1861 | |
| Lee et al. | Enhancing the cytotoxicity of immunotoxins by facilitating their dissociation from target receptors under the reducing conditions of the endocytic pathway | |
| Novakova et al. | Engineered fragments of the PSMA-specific 5D3 antibody and their functional characterization | |
| Jendryczko et al. | FGF2-derived peptibodyF2-MMAE conjugate for targeted delivery of cytotoxic drugs into cancer cells overexpressing FGFR1 |